Suppr超能文献

在不同环境中,超过 13000 名阿片类药物维持治疗患者和非治疗患者的全因和过量死亡率存在很大差异:一项比较登记关联研究。

Large variations in all-cause and overdose mortality among >13,000 patients in and out of opioid maintenance treatment in different settings: a comparative registry linkage study.

机构信息

First Faculty of Medicine, Department of Addictology, Charles University, Prague, Czechia.

Department of Addictology, General University Hospital in Prague, Prague, Czechia.

出版信息

Front Public Health. 2023 Sep 22;11:1179763. doi: 10.3389/fpubh.2023.1179763. eCollection 2023.

Abstract

BACKGROUND

Opioid maintenance treatment (OMT) has the potential to reduce mortality rates substantially. We aimed to compare all-cause and overdose mortality among OMT patients while in or out of OMT in two different countries with different approaches to OMT.

METHODS

Two nation-wide, registry-based cohorts were linked by using similar analytical strategies. These included 3,637 male and 1,580 female patients enrolled in OMT in Czechia (years 2000-2019), and 6,387 male and 2,078 female patients enrolled in OMT in Denmark (years 2007-2018). The direct standardization method using the European (EU-27 plus EFTA 2011-2030) Standard was employed to calculate age-standardized rate to weight for age. All-cause and overdose crude mortality rates (CMR) as number of deaths per 1,000 person years (PY) in and out of OMT were calculated for all patients. CMRs were stratified by sex and OMT medication modality (methadone, buprenorphine, and buprenorphine with naloxone).

RESULTS

Age-standardized rate for OMT patients in Czechia and Denmark was 9.7/1,000 PY and 29.8/1,000 PY, respectively. In Czechia, the all-cause CMR was 4.3/1,000 PY in treatment and 10.8/1,000 PY out of treatment. The overdose CMR was 0.5/1,000 PY in treatment and 1.2/1,000 PY out of treatment. In Denmark, the all-cause CMR was 26.6/1,000 PY in treatment and 28.2/1,000 PY out of treatment and the overdose CMR was 7.3/1,000 PY in treatment and 7.0/1,000 PY out of treatment.

CONCLUSION

Country-specific differences in mortality while in and out of OMT in Czechia and Denmark may be partly explained by different patient characteristics and treatment systems in the two countries. The findings contribute to the public health debate about OMT management and may be of interest to practitioners, policy and decision makers when balancing the safety and accessibility of OMT.

摘要

背景

阿片类药物维持治疗(OMT)有很大降低死亡率的潜力。我们旨在比较在两个采用不同 OMT 方法的国家中,接受 OMT 的患者在接受 OMT 治疗期间和结束 OMT 治疗后的全因死亡率和过量死亡率。

方法

通过使用相似的分析策略,将两个全国性的登记册为基础的队列进行了关联。这些队列包括 2000 年至 2019 年期间在捷克接受 OMT 的 3637 名男性和 1580 名女性患者,以及 2007 年至 2018 年期间在丹麦接受 OMT 的 6387 名男性和 2078 名女性患者。采用欧洲(欧盟 27 国加上欧洲自由贸易联盟 2011-2030 年)标准的直接标准化法计算按年龄标准化的率,以每 1000 人年(PY)的年龄加权。为所有患者计算了接受 OMT 治疗期间和结束 OMT 治疗后的全因和过量死亡率(CMR),以每 1000 人年(PY)的死亡人数表示。按性别和 OMT 药物治疗方式(美沙酮、丁丙诺啡和丁丙诺啡纳洛酮)对 CMR 进行分层。

结果

捷克和丹麦的 OMT 患者的年龄标准化率分别为 9.7/1000PY 和 29.8/1000PY。在捷克,治疗期间的全因 CMR 为 4.3/1000PY,治疗结束后的 CMR 为 10.8/1000PY。过量死亡率的 CMR 为治疗期间的 0.5/1000PY 和治疗结束后的 1.2/1000PY。在丹麦,治疗期间的全因 CMR 为 26.6/1000PY,治疗结束后的 CMR 为 28.2/1000PY,治疗期间的过量死亡率为 7.3/1000PY,治疗结束后的过量死亡率为 7.0/1000PY。

结论

捷克和丹麦在接受 OMT 治疗期间和结束 OMT 治疗后的死亡率存在国家特定差异,这可能部分归因于两国患者特征和治疗系统的差异。这些发现为关于 OMT 管理的公共卫生辩论做出了贡献,对于从业者、政策和决策者在平衡 OMT 的安全性和可及性时可能具有参考价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f62d/10558053/a3106f0597a3/fpubh-11-1179763-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验